title: Various anti-motion sickness drugs and core body temperature changes.
abstract: BACKGROUND
  Blood flow changes and inactivity associated with motion sickness appear to exacerbate the rate of core temperature decrease during subsequent body cooling. We investigated the effects of various classes of anti-motion sickness drugs on core temperature changes.
  
  
  METHODS
  There were 12 healthy male and female subjects (20-35 yr old) who were given selected classes of anti-motion sickness drugs prior to vestibular Coriolis cross coupling induced by graded yaw rotation and periodic pitch-forward head movements in the sagittal plane. All subjects were then immersed in water at 18 degrees C for a maximum of 90 min or until their core temperature reached 35 degrees C. Double-blind randomized trials were administered, including a placebo, a non-immersion control with no drug, and six anti-motion sickness drugs: meclizine, dimenhydrinate, chlorpheniramine, promethazine + dexamphetamine, promethazine + caffeine, and scopolamine + dexamphetamine. A 7-d washout period was observed between trials. Core temperature and the severity of sickness were monitored throughout each trial.
  
  
  RESULTS
  A repeated measures design was performed on the severity of sickness and core temperature changes prior to motion provocation, immediately after the motion sickness end point, and throughout the period of cold-water immersion. The most effective anti-motion sickness drugs, promethazine + dexamphetamine (with a sickness score/duration of 0.65 +/- 0.17) and scopolamine + dexamphetamine (with a sickness score/duration of 0.79 +/- 0.17), significantly attenuated the decrease in core temperature. The effect of this attenuation was lower in less effective drugs.
  
  
  CONCLUSIONS
  Our results suggest that the two most effective anti-motion sickness drugs are also the most effective in attenuating the rate of core temperature decrease.
authors.affiliation: DRDC-Toronto, 1133 Sheppard Ave. W., Toronto, Ontario M3M 309, Canada. bob.cheung@drdc-rddc.gc.ca
authors.forename: Bob
authors.initials: B
authors.lastname: Cheung
authors.forename: Ann M
authors.initials: AM
authors.lastname: Nakashima
authors.forename: Kevin D
authors.initials: KD
authors.lastname: Hofer
mesh_terms: D000328:Adult; D000932:Antiemetics / Q000627:therapeutic use*; D001831:Body Temperature / Q000187:drug effects*; D003312:Coriolis Force; D003913:Dextroamphetamine / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009041:Motion Sickness / Q000188:drug therapy* / Q000503:physiopathology*; D011398:Promethazine / Q000627:therapeutic use*; D012601:Scopolamine / Q000627:therapeutic use*; D014722:Vestibule, Labyrinth / Q000502:physiology*; D055815:Young Adult
chemical_list: D000932:Antiemetics; D012601:Scopolamine; D011398:Promethazine; D003913:Dextroamphetamine